You have access
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site
NAOTAKA NISHIYAMA, YUKI KITA, KATSUHIRO ITO, MINORU KATO, SHINGO HATAKEYAMA, YUTO MATSUSHITA, SEI NAITO, MAKITO MIYAKE, SHOTARO NAKANISHI, YOICHIRO KATO, TADAMASA SHIBUYA, TETSUTARO HAYASHI, HIROAKI YASUMOTO, TAKASHI YOSHIDA, MOTOHIDE UEMURA, RIKIYA TAOKA, HIROYUKI NISHIYAMA, TAKASHI KOBAYASHI and HIROSHI KITAMURA; on behalf of the Japan Urological Oncology Group
Anticancer Research November 2023, 43 (11) 5041-5050; DOI: https://doi.org/10.21873/anticanres.16703
